FDA 483 OBSERVATION · #1269 OF 1,932 MOST-CITED

Review and approval of procedures

FDA cited this observation 11 times across 11 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Human Tissue for Transplantation11
BY FISCAL YEAR
FY20242
FY20231
FY20222
FY20191
FY20181
FY20164

How FDA worded it — real examples

Donor eligibility procedures were not reviewed and approved by a responsible person before implementation.

Marwan M. Shaykh, M.D. · Jacksonville, Florida · Human Tissue for Transplantation · 2024-08-28

Donor eligibility procedures were not reviewed and approved by a responsible person before implementation.

Envita Fertility Center · Laguna Hills, California · Human Tissue for Transplantation · 2023-10-06

Donor eligibility procedures were not reviewed and approved by a responsible person before implementation.

Pelex Medical of Texas · Lubbock, Texas · Human Tissue for Transplantation · 2023-07-28

Donor eligibility procedures were not reviewed and approved by a responsible person before implementation.

University of Alabama at Birmingham Gamete Biology Lab · Birmingham, Alabama · Human Tissue for Transplantation · 2022-03-23

Donor eligibility procedures were not reviewed and approved by a responsible person before implementation.

Fangyinmeng MD Inc. · Irvine, California · Human Tissue for Transplantation · 2021-10-22

Donor eligibility procedures were not reviewed and approved by a responsible person before implementation.

Los Angeles IVF Laboratory · Encino, California · Human Tissue for Transplantation · 2018-10-19

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality system →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →